Profile data is unavailable for this security.
About the company
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
- Revenue in USD (TTM)1.00k
- Net income in USD-18.36m
- Incorporated1984
- Employees6.00
- LocationErnexa Therapeutics Inc1035 Cambridge Street, Suite 18ACAMBRIDGE 02141United StatesUSA
- Phone+1 (617) 798-6700
- Fax+1 (302) 655-5049
- Websitehttps://www.ernexatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 7.48m | 1.00 | -- | 2.64 | -- | 1,246.10 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| Pulmatrix Inc | 0.00 | -5.16m | 7.56m | 2.00 | -- | 1.98 | -- | -- | -1.41 | -1.41 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -73.31 | -41.17 | -80.51 | -46.40 | -- | -- | -- | -257.55 | -- | -- | 0.00 | -- | -100.00 | -- | 46.00 | -- | -- | -- |
| Aclarion Inc | 67.48k | -7.39m | 7.65m | 6.00 | -- | 0.1249 | -- | 113.36 | -1,687.50 | -1,687.50 | 0.1948 | 21.46 | 0.0082 | -- | 2.76 | 11,246.67 | -89.50 | -- | -97.72 | -- | -7.85 | -- | -10,868.49 | -- | -- | -25,428.22 | 0.00 | -- | -39.36 | -- | -43.60 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -10.85m | 7.72m | 27.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.6973 | 0.00 | -- | -- | 0.00 | -637.06 | -112.30 | -- | -219.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.39 | -- | -- | -- |
| Biomx Inc | 0.00 | -36.20m | 7.76m | 20.00 | -- | -- | -- | -- | -23.69 | -23.69 | 0.00 | -0.817 | 0.00 | -- | -- | 0.00 | -147.70 | -62.93 | -210.64 | -78.33 | -- | -- | -- | -- | -- | -41.56 | -- | -- | -- | -- | -104.20 | -- | -71.20 | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.79m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 8.00m | 9.00 | -- | -- | -- | 20.52 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Bolt Biotherapeutics Inc | 5.20m | -42.68m | 8.29m | 52.00 | -- | 0.2583 | -- | 1.60 | -22.27 | -22.27 | 2.71 | 16.72 | 0.0596 | -- | -- | 99,903.84 | -48.95 | -46.54 | -58.33 | -52.20 | -- | -- | -821.58 | -1,666.52 | -- | -- | 0.00 | -- | -2.36 | 104.50 | 8.79 | -- | -39.55 | -- |
| Calcimedica Inc | 0.00 | -23.06m | 8.35m | 14.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0188 | 0.00 | -- | -- | 0.00 | -148.18 | -58.12 | -194.91 | -64.99 | -- | -- | -- | -- | -- | -- | 1.03 | -- | -- | -- | 60.12 | -- | -57.90 | -- |
| Ernexa Therapeutics Inc | 1.00k | -18.36m | 8.60m | 6.00 | -- | 0.6554 | -- | 8,598.35 | -5.32 | -5.32 | 0.0002 | 0.4548 | 0.0001 | -- | 0.0059 | 166.67 | -264.07 | -187.10 | -2,044.59 | -237.72 | 100.00 | -- | -1,834,000.00 | -3,375.91 | -- | -2.73 | 0.00 | -- | 755.88 | -50.61 | -105.47 | -- | -19.54 | -- |
| Cardio Diagnostics Holdings Inc | 15.79k | -6.55m | 8.66m | 13.00 | -- | 1.03 | -- | 548.16 | -4.07 | -4.07 | 0.0097 | 4.61 | 0.0024 | -- | 1.25 | 1,214.62 | -98.75 | -- | -104.31 | -- | -- | -- | -41,495.31 | -- | -- | -440.22 | 0.00 | -- | 104.39 | -- | -0.079 | -- | -- | -- |
| Liminatus Pharma Inc | 0.00 | -2.27m | 9.05m | -- | -- | -- | -- | -- | -0.0872 | -0.0872 | 0.00 | -0.0608 | 0.00 | -- | -- | -- | -77.46 | -- | -- | -- | -- | -- | -- | -- | -- | -12.30 | -- | -- | -- | -- | 28.85 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -27.16m | 9.40m | 7.00 | -- | 5.99 | -- | -- | -354.09 | -354.09 | 0.00 | 1.71 | 0.00 | -- | -- | 0.00 | -592.26 | -153.21 | -1,387.56 | -219.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.49 | -- | -- | -- |
| Lunai Bioworks Inc | 0.00 | -125.52m | 9.55m | 29.00 | -- | -- | -- | -- | -7.14 | -7.14 | 0.00 | -0.5602 | 0.00 | -- | -- | 0.00 | -212.74 | -75.79 | -361.75 | -85.18 | -- | -- | -- | -- | -- | -23.72 | -- | -- | -- | -- | -101.31 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to Ernexa Therapeutics Inc's reporting currency: US Dollar USD
1.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Corient Private Wealth LLCas of 31 Dec 2025 | 438.09k | 1.41% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 25.45k | 0.08% |
| Geode Capital Management LLCas of 31 Dec 2025 | 23.62k | 0.08% |
| Gesalcal� SA SGIICas of 31 Dec 2025 | 13.42k | 0.04% |
| HRT Financial LPas of 31 Dec 2025 | 12.63k | 0.04% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 10.48k | 0.03% |
| Sippican Capital Advisors LLCas of 31 Dec 2025 | 10.00k | 0.13% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 820.00 | 0.00% |
| UBS Securities LLCas of 31 Dec 2025 | 600.00 | 0.00% |
| AssetMark, Inc.as of 31 Dec 2025 | 133.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
